secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-11-10T21:08:52+00:00
Accession:  0001437749-26-036164
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin: Annamycin plus PD-1 blockade extends survival in pancreatic cancer preclinical models
--------------------------------------------------------------------------------

- In an immunocompetent KPC mouse model of advanced pancreatic ductal adenocarcinoma, liposomal Annamycin (L-ANN) plus PD-1 blockade increased survival vs either agent alone; reconfirmed independently.
- Annamycin reached substantially higher and more sustained pancreatic tissue exposure than doxorubicin at the same dose, with increased CD8+ cytotoxic and CD4+ helper T-cell infiltration.
- Depleting CD8+ T cells shortened survival in treated mice, showing the immune system contributes to Annamycin's antitumor activity rather than being a bystander.
- Data presented Nov 10, 2026 by Waldemar Priebe, PhD of MD Anderson at the Marie Sklodowska-Curie Symposium in Tampa, building on AACR April and September 2026 results.
- CEO Walter Klemp said the priority remains the MIRACLE AML trial with a Q1 2027 data readout; Moleculin plans to sponsor an investigator-initiated pancreatic cancer trial in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/0001437749-26-036164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/mbrx20261109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-036164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer